Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) [Yahoo! Finance]
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Novogen (NASDAQ:KZIA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
Novogen (NASDAQ:KZIA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.